System, device, and method that amplify a signal of lateral flow assay

JP2024074809A5Active Publication Date: 2024-11-12BECTON DICKINSON & CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024034029
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-06-18
Filing Date
2024-03-06
Publication Date
2024-11-12
Estimated Expiration
2039-06-06

AI Technical Summary

Technical Problem

Lateral flow assays struggle to reliably detect analytes present in small amounts or concentrations due to signals falling below the detection threshold of measurement systems, leading to false negatives.

Method used

The implementation of a signal amplification conjugate in lateral flow assays that binds to unbound analyte-specific conjugates, forming a chain reaction to increase the signal intensity above the detection threshold, enhancing sensitivity and accuracy.

Benefits of technology

The method significantly improves the sensitivity of lateral flow assays to detect and quantify analytes at low concentrations, reducing false negatives and enabling reliable detection in point-of-care settings without complex sample preparation.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

To provide a lateral flow assay device, system, and method.SOLUTION: The lateral flow assay device, system, and method detect analytes present in a sample in small amounts or at low concentrations by amplifying signals generated in a detection zone. Signals generated can exceed a detection threshold of a measurement system, increasing the sensitivity of the lateral flow assay device, system and method. In one aspect, the lateral flow device includes a signal-amplifying conjugate that binds to a complex that is bound to an immobilized capturing material in the detection zone, generates a chain reaction of binding events in the detection zone, resulting in amplification of the signal generated in the detection zone.SELECTED DRAWING: Figure 4
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 62 / 686,606, filed June 18, 2018, which is incorporated by reference in its entirety.

[0002] The present disclosure relates generally to lateral flow devices, test systems and methods. More particularly, the present disclosure relates to a lateral flow assay device capable of measuring analytes present in small or low concentration samples by amplifying the detection signal. [Background technology]

[0003] Immunoassay systems, including lateral flow assays, provide reliable, inexpensive, small, rapid and simple diagnostic tests. Lateral flow assays can quickly and accurately detect, and in some cases, quantitate, the presence or absence of an analyte of interest in a sample. Advantageously, lateral flow assays are minimally invasive and can be used as point-of-care testing systems. Lateral flow assays generate a signal that can be measured to indicate the presence or absence or amount of an analyte of interest in a sample. If the analyte is present in a sample in small amounts or concentrations, however, the signal generated by the labeled analyte captured in the test zone of the lateral flow assay may not exceed the detection threshold of the measurement system that reads and processes the signal. As a result, the lateral flow assay may not reliably or accurately indicate that the analyte of interest is present in the sample. Summary of the Invention

[0004] summary Thus, an aspect of the present disclosure is to provide an improved lateral flow assay that can detect the presence, absence, or amount of an analyte in a sample. The methods and system embodiments described herein can measure the presence, and in some cases the amount or concentration, of an analyte, even when the analyte is present in small amounts or at low concentrations, where a signal would normally be generated at a level below the detection threshold of the measurement system. As a result, the system, device, and method embodiments described herein are highly sensitive to the analyte of interest, even in small amounts or at low concentrations. Furthermore, the methods and system embodiments described herein can determine the absence of the analyte of interest in a sample with greater confidence than prior methods and systems. The absence of a detectable signal in the embodiments of the present disclosure can reliably indicate the absence of the analyte of interest in the sample (as opposed to an analyte that is actually present, but at such low concentrations that the signal generated is below the detection threshold of the system). Thus, the embodiments of the present disclosure can reduce false negative readings. As described in detail below, the lateral flow assays described in the present disclosure amplify the signal generated in a test area, such as the capture zone of a lateral flow assay, to a level that allows a conventional measurement system to detect the analyte of interest present in a small amount or at low concentration of the sample.

[0005] The signals generated by the assays described in this disclosure are described herein in the context of optical signals generated by reflectance-based labels, such as, but not limited to, gold nanoparticle labels and latex particles of different colors. Although embodiments of the present disclosure are described herein with reference to "optical" signals, it will be understood that the assays described herein can use any suitable material for the labels to generate a signal, including, but not limited to, fluorescent latex bead labels, which generate a fluorescent signal, and magnetic nanoparticle labels, which generate a signal indicative of a change in a magnetic field associated with the assay. The lateral flow assay embodiments described herein are particularly advantageous in diagnostic tests where the analyte of interest is present on the test strip in small amounts or concentrations. The analyte of interest may be present on the test strip in low concentrations for a number of reasons, including but not limited to a limited amount of the analyte of interest in the sample applied to the test strip and a limited volume of the sample applied to the test strip. Although embodiments of the present disclosure are described in connection with detecting analytes of interest at low concentrations, it will be understood that the present disclosure can also detect small amounts of analytes of interest.

[0006] Some embodiments disclosed herein relate to a lateral flow assay for detecting an analyte of interest in a sample. The lateral flow assay comprises a first conjugate comprising a first label, an agent configured to specifically bind to the analyte of interest, and a first binding partner; a second conjugate upstream of the first conjugate along the fluid flow path of the lateral flow assay, the second conjugate comprising a second label and a second binding partner configured to specifically bind to the first binding partner; and a detection zone downstream of the first conjugate and the second conjugate along the fluid flow path of the lateral flow assay, the detection zone comprising an immobilized capture agent (immobilized capture agent) that specifically binds to the analyte of interest. The first conjugate can be present in a sample receiving zone of a lateral flow assay, or the first conjugate is present in a first conjugate zone downstream of the sample receiving zone. The second conjugate can be present in a buffer receiving zone upstream of the sample receiving zone, or the second conjugate is present in a second conjugate zone downstream of the buffer receiving zone and upstream of the sample receiving zone. The first conjugate can be configured to be solubilized and migrate (collect) to the detection zone upon application of a fluid sample to the lateral flow assay. The second conjugate can be configured to be solubilized and migrate to the detection zone after the first conjugate has migrated to the detection zone.

[0007] The agent configured to specifically bind to the analyte of interest may be an antibody or an antibody binding fragment that specifically binds to the analyte of interest. The first and second binding partners may comprise a binding pair selected from the group consisting of antigen / antibody, hapten / antibody, hormone / receptor, nucleic acid strand / complementary nucleic acid strand, substrate / enzyme, inhibitor / enzyme, carbohydrate / lectin, biotin / avidin, receptor / ligand, and virus / cell receptor. The first and second binding partners may comprise a biotin / avidin binding pair, where the avidin may comprise streptavidin or neutravidin. The first and second binding partners may comprise an antigen / antibody binding pair, where the antigen may comprise a peptide or decapeptide. The analyte of interest may be a biological or environmental substance of interest. The analyte of interest may be an influenza virus. The influenza virus may be an influenza A virus, an influenza B virus, or an influenza C virus. The immobilized capture agent may be an antibody or an antibody binding fragment that specifically binds to the analyte of interest. The test strip may comprise a nitrocellulose membrane. The lateral flow assay may also comprise a control zone comprising an immobilized capture agent that specifically binds to the first conjugate.

[0008] The first and second labels may be selected from the group consisting of metal nanoparticles, blue latex beads, metal nanoparticles, colored latex particles, colored latex beads, magnetic particles, carbon nanoparticles, quantum dots, up converting phosphors, organic fluorophores, textile dyes, enzymes or liposomes. The first and second labels may comprise gold nanoparticles. The first and second labels may be configured to generate an optical, fluorescent or magnetic signal. The lateral flow assay may also include a housing including a sample well located laterally above or upstream of the first conjugate, a buffer well located laterally above or upstream of the second conjugate zone, and a read window accessible to the detection zone. The buffer well, the second conjugate zone, the sample receiving well, and the first conjugate zone may be spatially separated along the fluid flow path of the lateral flow assay. Further embodiments disclosed herein relate to a method for making a lateral flow assay. The method includes applying a first conjugate to a sample receiving zone of a lateral flow test strip or downstream of the lateral flow test strip, and applying a second conjugate to a buffer receiving zone upstream of the sample receiving zone or downstream of the test strip. The first conjugate and the second conjugate can be applied to the test strip simultaneously. The first conjugate and the second conjugate can be applied to the test strip by air jet deposition.

[0009] Other embodiments described herein relate to a method for detecting an analyte of interest in a sample. The method includes applying the sample to a lateral flow assay. The lateral flow assay includes a first conjugate comprising a first label, an agent configured to specifically bind to the analyte of interest, and a first binding partner; a second conjugate upstream of the first conjugate along the fluid flow path of the lateral flow assay, the second conjugate comprising a second label and a second binding partner configured to specifically bind to the first binding partner; and a detection zone downstream of the first conjugate and the second conjugate along the fluid flow path of the lateral flow assay, the detection zone comprising an immobilized capture agent that specifically binds to the analyte of interest. The method also includes binding a complex to the immobilized capture agent at the detection zone, the complex comprising the analyte of interest bound to the first conjugate. After binding the complex, the method includes releasing the second conjugate to flow along the fluid flow path of the lateral flow assay. The method further comprises binding a second conjugate to the bound complex at the detection zone.

[0010] The method may include detecting a signal generated by the bound complex and the second conjugate at the detection zone. The method may also include binding the first conjugate that is not bound to the analyte of interest to the second conjugate bound to the complex at the detection zone. The first label and the second label may be configured to generate an optical signal, a fluorescent signal, or a magnetic signal. After applying the sample to the lateral flow device, the second conjugate may be released at 5 seconds, 10 seconds, 15 seconds, 20 seconds, 25 seconds, 30 seconds, 35 seconds, 40 seconds, 45 seconds, 50 seconds, 55 seconds, 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, or 10 minutes. Binding the complex to the capture agent immobilized at the detection zone may include labeling the analyte of interest with a first conjugate to form a complex and binding the complex to the capture agent immobilized at the detection zone. Releasing the second conjugate may include applying a buffer to the second conjugate or to a location in the lateral flow assay upstream of the second conjugate. Applying the buffer may include pouring the buffer into a buffer receiving well located above or upstream of the second conjugate to the side. [Brief description of the drawings]

[0011] [Figure 1] FIG. 1 shows a top view of an exemplary lateral flow device according to the present disclosure including a buffer well, a sample well and a read window. [Diagram 2] 1 shows an exemplary assay test strip for a lateral flow signal amplification assay according to the present disclosure. [Diagram 3] 1 illustrates a schematic of an exemplary method for amplifying a signal generated by an assay test strip according to the present disclosure. [Figure 4]1 shows the results of a signal amplification reaction of a lateral flow device performed in accordance with the present disclosure, showing signal intensity as a function of read time for a control signal (absence of signal amplification conjugate-◆) and a test signal (with signal amplification conjugate-■). [Diagram 5] 1 shows the results of a signal amplification reaction of a lateral flow device performed in accordance with the present disclosure, showing signal intensity as a function of analyte concentration, including control signals of an assay performed without signal amplification conjugate after 10 minutes (◆) and 20 minutes (▲), and test signals in the presence of signal amplification conjugate after 10 minutes (■) and 20 minutes (●). [Figure 6] 1 shows a flow diagram for an exemplary method of using a lateral flow assay to detect an analyte of interest in a sample at low concentration. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] A typical lateral flow sandwich assay includes a test strip with a conjugate pad (or labeling zone), a capture or test zone, and an absorbent pad aligned along the fluid flow path, usually but not necessarily aligned along the longitudinal axis of the test strip. The test strip may include a sample receiving zone or well upstream of the conjugate pad. The conjugate pad typically includes a labeled analyte-specific antibody, called a conjugate. The label of the conjugate may include an analyte-specific antibody bound to a sensing molecule, such as but not limited to a gold nanoparticle. The capture zone includes an immobilized capture substance, e.g., an analyte-specific antibody immobilized on a carrier material, such as a nitrocellulose membrane. The absorbent pad assists the liquid sample applied to the conjugate pad (or sample receiving zone, if present) to flow through the carrier material to the capture zone. When the liquid sample is applied to the test strip (in the sample receiving zone or conjugate pad), the labeled analyte-specific antibody becomes rehydrated and mobilizable. If an antibody-specific analyte of interest is present, the analyte binds to the labeled analyte-specific antibody, forming an analyte-antibody-sensing agent complex that migrates through the carrier material downstream in the test zone. In the test zone, the analyte in the analyte-antibody-sensing agent complex interacts with an analyte-specific antibody immobilized in the capture zone to form an antibody-analyte-antibody-sensing agent structure, commonly referred to as a sandwich. When a threshold number of these sandwich structures are formed in the capture zone, the signal generated by the sensing molecule in the sandwich structure can be detected by the measurement system.

[0013] The measurement system can process the detected signal to determine the presence, and in some cases the amount, of the analyte of interest in the sample. If the analyte of interest is not present in the sample, no analyte-antibody-detector complex is formed, and as a result, no sandwich structure is formed in the capture zone. In this example, there is no detector molecule in the capture zone, and the measurement system correlates the absence of signal from the capture zone with the absence of the analyte of interest in the sample. In cases where the analyte of interest is actually present in the sample, but in very small amounts or at low concentrations, the number of sandwich structures formed in the capture zone may be very small. In some examples, the number of sandwich structures is so small that the signal generated by the detector molecule is below the detection threshold of the measurement system. In this case, the measurement system correlates the absence of signal from the capture zone (or the absence of signal above the detection threshold of the system) with the absence of the analyte of interest in the sample, even though the analyte of interest is actually present in the sample, but in very small amounts or at low concentrations. Thus, typical lateral flow sandwich assays have limited sensitivity to analytes of interest present in small amounts or at low concentrations.

[0014] The devices, systems and methods described herein address these and other shortcomings by amplifying the signal generated in the presence of an analyte of interest in a sample applied to a lateral flow assay. Advantageously, embodiments of the devices, systems and methods described in this disclosure can amplify the signal generated in a test region, such as a capture zone, of a lateral flow assay to a level above the detection threshold of a typical reader, even when the analyte of interest is present at low concentrations. The lateral flow devices, test systems and methods described in this disclosure include a signal amplification conjugate that binds to both (1) a first analyte-specific conjugate that is bound to the immobilized capture material of the capture zone, and (2) a second residual analyte-specific conjugate that is present in the capture zone but is not bound to the immobilized capture material. This second, previously unbound, residual analyte-specific conjugate (which has been bound to the first signal amplification conjugate at the capture zone) contains an additional binding site that interacts with and binds to the second signal amplification conjugate, which itself interacts with and binds to a third residual analyte-specific conjugate present in the capture zone, and so on, in a multi-level chain reaction of binding events at the capture zone.

[0015] The presence of additional analyte-specific conjugates that become bound to the capture zone, by binding interaction with the signal amplification conjugate, can increase the intensity of the signal generated at the capture zone to a level above the detection threshold of a normal measurement system. The presence of signal amplification conjugates bound to the capture zone can also increase the intensity of the signal generated at the capture zone to a level above the detection threshold of a normal measurement system. The embodiments of the present disclosure improve the sensitivity of the lateral flow assay by increasing the signal generated by the lateral flow assay to a normal detectable range rather than modifying the characteristics of the measurement system, and advantageously make the lateral flow assays described in the present disclosure backward compatible with normal lateral flow assay test systems.

[0016] Without being bound to any particular theory, it is believed that the signal amplification conjugate typically forms a scaffold that can capture and hold additional analyte-specific conjugates that would otherwise pass through the capture zone, resulting in the generation of an amplified signal at the capture zone. In addition to the sensing molecule in the analyte-specific conjugate, the signal amplification conjugate can also include a sensing molecule, and the signal amplification conjugate that becomes bound to the capture zone also generates a signal at the capture zone, thereby contributing to increasing the intensity of the signal generated at the capture zone to a level above the detection threshold. Advantageously, embodiments of the present disclosure do not rely on or require that all or substantially all of the analyte of interest present in the sample bind to both the analyte-specific conjugate and the immobilized capture material at the capture zone in order to amplify the signal at the capture zone. An advantage of the present disclosure is that even at very low levels of the analyte of interest bound to the analyte-specific conjugate and the capture material immobilized at the capture zone (e.g., in the case of a sample having a low concentration of the analyte of interest present), some amount, in some cases very small amount, of the analyte of interest can initiate a chain reaction of binding events at the capture zone, regardless of the presence or absence of the analyte of interest in the scaffold formed after binding to the capture material immobilized at the capture zone. Thus, embodiments of the systems, devices and methods described herein can significantly improve the sensitivity of lateral flow assays for the analyte of interest present in a sample, even in trace amounts.

[0017] In addition to increasing the sensitivity of lateral flow assays to measure the presence or amount of an analyte of interest in a sample at low concentration, the devices, systems, and methods described herein can be advantageously performed in a point-of-care setting without the use of highly specialized, and in some cases time-consuming, sample preparation techniques and detection systems that are typically used to analyze analytes in samples at low concentration, such as polymerase chain reaction (PCR). The lateral flow device embodiments described herein provide a convenient, easy-to-use format for the user, rapidly generate a signal that can be detected by a conventional reader, and can be performed in a point-of-care setting rather than an off-site laboratory. The description is intended to be an example of a test strip for measuring an analyte of interest in a test sample, even if it is present at a low concentration.Those skilled in the art will recognize that this example is intended to be illustrative, and that various modifications and variations can be used in the lateral flow assay described herein.For example, a sample can contain one or more analytes of interest that are present at a low concentration, and the assay test strip can measure one or more analytes of interest.In each of the various iterations, the lateral flow assay includes the feature described in the present disclosure that amplifies the signal at the detection zone for measuring the analyte of the test sample. Where more than one analyte of interest is to be detected, e.g., multiple analytes of interest in a sample, the detection zone may comprise separate capture zones specific for each of the analytes of interest. For example, a sample may comprise three analytes of interest: a first analyte of interest, a second analyte of interest, and a third analyte of interest. The detection zone of a lateral flow assay would thus comprise three capture zones: a first capture zone specific for the first analyte of interest, a second capture zone specific for the second analyte of interest, and a third capture zone specific for the third analyte of interest.

[0018] Thus, the present disclosure provides assay test strips for measuring an analyte of interest in a test sample, even when present at low concentrations, lateral flow assays including the test strips, methods of measuring an analyte of interest using the test strips described herein, and methods of making the assay test strips described herein. The lateral flow assay embodiments described herein are particularly advantageous in diagnostic tests where the analyte of interest is present on the test strip in small amounts. Although embodiments of the present disclosure are described herein in the context of low amounts of analyte present on the test strip, where the analyte is present in a sample at low concentrations, it will be understood that embodiments of the present disclosure are also applicable where the sample contains an amount of analyte capable of generating a signal above the detection threshold, but where only a limited amount of sample is applied to the test strip.

[0019] Various aspects of the device, test system and method will be described more fully hereinafter in connection with the accompanying drawings. However, the present disclosure may be embodied in many different forms. Based on the teachings of this specification, a person skilled in the art will recognize that the scope of the present disclosure is intended to cover any aspect of the device, test system and method disclosed herein, whether implemented independently or in combination with any other aspect of the present disclosure. For example, an apparatus may be implemented or a method may be performed using any number of the aspects described herein. Although specific aspects are described herein, many variations and permutations of these aspects are within the scope of the present disclosure. Although certain benefits and advantages are mentioned, the scope of the present disclosure is not intended to be limited to specific benefits, applications or purposes. Rather, the aspects of the present disclosure are intended to be broadly applicable to different detection techniques and device configurations, some of which are shown for illustrative purposes in the figures and the following description.

[0020] Conventional lateral flow device The lateral flow device described herein is an analytical device used for lateral flow chromatography. A lateral flow assay is an assay that can be performed with the lateral flow device described herein. The lateral flow device can be implemented in an assay test strip, but can also be applied in other forms, such as urine test strips, flow-through devices, or microfluidic devices. In a test strip format, a fluid sample containing or believed to contain an analyte is placed in a sample receiving zone. The analyte of interest is labeled after contacting the test strip. The now labeled analyte of interest then flows (e.g., by capillary action) through the test strip. The test strip may be made of a medium such as paper, nitrocellulose, cellulose, fiber, or nylon, or other material that allows the sample to flow through the medium.

[0021] Such assays are called sandwich assays. The sandwich assays described in this disclosure are described in the context of reflective labels (gold nanoparticle labels and latex particles of different colors) that generate optical signals, but it will be understood that the assays described in this disclosure can include latex bead labels configured to generate fluorescent signals, magnetic nanoparticle labels configured to generate magnetic signals, or any other labels configured to generate detectable signals. The sandwich-type lateral flow assay includes a labeled conjugate that is attached to a sample receiving zone of a solid substrate. After the sample is applied to the sample receiving zone, the labeled conjugate dissolves or solubilizes in the sample, where the labeled conjugate recognizes and specifically binds to a first epitope on the analyte of the sample, forming a label-conjugate-analyte complex. This complex flows along the liquid front from the sample receiving zone through the solid substrate to a detection zone (sometimes called a "test line" or "capture zone") where an immobilized capture agent (e.g., an immobilized analyte-specific antibody) is placed. In some cases where the analyte is multimeric or contains multiple identical epitopes in the same monomer, the labeled conjugate attached to the sample receiving zone may be the same as the capture agent immobilized in the detection zone. The immobilized capture agent recognizes and specifically binds to an epitope in the analyte, thereby capturing the label-conjugate-analyte complex in the detection zone. The presence of the labeled conjugate in the detection zone provides a detectable signal in the detection zone if the analyte is present in sufficient quantity. In one non-limiting example, gold nanoparticles are used to label the conjugate because they are relatively inexpensive, stable, and provide an easily observable color indication due to the surface plasmon resonance properties of gold nanoparticles.

[0022] Detecting the signal generated in the detection zone can indicate that the analyte of interest is present in the sample. For example, if the signal is above the detection threshold of the measurement system, the measurement system can detect its presence and, in some cases, can quantify the analyte of the sample. However, the lack of any detectable signal in the detection zone can indicate that the analyte of interest is not present in the sample or may be present below the detection limit. For example, if the sample does not contain any analyte of interest, the sample will have solubilized the labeled conjugate, and the labeled conjugate will still flow to the detection zone. The labeled conjugate, however, will not bind to the immobilized conjugate in the detection zone. The labeled conjugate will instead flow through the detection zone, through the control line (if present), and in some cases to any absorption zone. Some labeled conjugates will bind to the control substance attached to the control line and generate a detectable signal in the control line, indicating that the device is operating properly. If the analyte is present, but in an amount below the detection limit, the label-conjugate-analyte complex will bind but not be detected in the detection zone. Under these circumstances, the lack of a detectable signal emanating from the detection zone means that the user cannot conclusively determine whether the analyte is absent from the sample or is present in the sample below the detection limits of the measurement system.

[0023] Exemplary lateral flow signal-amplification devices described in this disclosure The lateral flow assays, test systems and methods described herein address these and other shortcomings of lateral flow assays, which cannot distinguish between the absence of an analyte in a sample and the presence of an analyte in an amount below the limit of detection. In addition to improving the quantitative measurement of an analyte, embodiments of the assays, test systems and methods of the present disclosure can also significantly increase the sensitivity of measurements made by conventional readers, in some cases enabling quantitative measurement of an analyte.

[0024] FIG. 1 shows an example of a lateral flow device 100 according to the present disclosure. An assay test strip is received in a housing of the device 100. In this non-limiting example of a lateral flow device 100, the housing defines a buffer well 110, a sample well 120 and a reading window 130. The lateral flow device 100 can be sized and shaped to facilitate ease of use, rapidly deliver test results, be portable, function properly with an automated reader, be deployed, reduce materials and costs used, or other considerations. The size and shape are therefore not limited to any particular size or shape, but can be readily modified to fit the particular needs or requirements of a particular situation of use. Figure 2 shows an example of an assay test strip 101 according to the present disclosure. The assay test strip 101 may be received or accommodated in the lateral flow device 100 of Figure 1. The example assay test strip 101 in this non-limiting embodiment includes a sample receiving zone and a buffer receiving zone, a substrate having a detection zone and an absorbent pad, an assay membrane. It will be understood that the present disclosure is not limited to this example assay test strip and that other test strips having different characteristics may be implemented in accordance with the present disclosure.

[0025] In the embodiment of Figure 2, assay test strip 101 includes a back card 102, a conjugate pad 103 having a sample receiving zone 121 and a buffer receiving zone 111, a membrane having a detection zone 131, and a membrane 104 having an absorbent pad 105. Membrane 104 may be a nitrocellulose material. Assay test strip 101 is contained in a lateral flow device 100, with buffer receiving zone 111 accessible by buffer well 110, sample receiving zone 121 accessible by sample well 120, and detection zone 131 accessible by read window 130. The result of the assay may be measured at read window 130 by measuring the signal, if any, generated at detection zone 131. The back card 102 may be any suitable material sufficient to support the assay test strips, for example, a water impermeable layer of solid plastic, a laminated sheet, a composite material, etc. The absorbent pad 105 helps promote capillary action and fluid flow through the membrane, and may comprise any suitable material for absorbing fluids, including, for example, nitrocellulose, cellulose-derived materials, porous polyethylene pads, glass fiber filter paper, etc. The absorbent material may be treated with a surfactant to aid in the water absorption process.

[0026] Fluid is configured to flow from the conjugate pad 103 to the absorbent pad 105 along the longitudinal axis of the assay test strip 101. The components of the assay test strip 101 are described with reference to this direction of fluid flow. For example, the membrane 104 is downstream of the conjugate pad 103 and upstream of the absorbent pad 105. For example, the sample receiving zone 121 is downstream of the buffer receiving zone 111 and upstream of the detection zone 131. The detection zone 131 of the membrane 104 includes an immobilized capture substance configured to specifically bind the analyte of interest when present in the sample. The membrane 104 may further include additional detection zones for detecting one or more analytes of interest and may include one or more control zones. The membrane 104 may be transparent in the visible range to minimize undesired read interferences to accurately determine the presence and / or amount of the analyte of interest. The capture substance may be immobilized on or within the membrane 104 using any suitable method including, for example, attaching, spraying, soaking, immersing, pouring, or injecting the capture substance onto or within the membrane 104. For example, the capture substance may be attached and immobilized on the membrane 104 by preparing a solution including the capture substance and spraying the solution onto the membrane 104 with an air jet technique. In another example, the capture agent is attached by preparing a solution having the capture agent, injecting the solution, spraying the solution, formulating the solution as a powder or gel that is placed or rubbed onto the test strip, or in any other suitable manner.

[0027] The capture material can be immobilized in any suitable amount at the detection zone 131 of the assay test strip 101. Advantageously, embodiments of the present disclosure can detect the presence and amount of low concentrations of an analyte of interest using a type of capture material and amounts typical of conventional lateral flow sandwich assays. In some embodiments, the immobilized capture material is present in an amount ranging from about 0.1-20 μL per test strip. The conjugate pad 103, in this exemplary implementation, is placed on a portion of the back card 102. When the assay test strip 101 is housed in the lateral flow device 100, the buffer receiving zone 111 is accessible by the buffer well 110, in this case disposed laterally below the buffer well 110. The sample receiving zone 121 is accessible by the sample well 120, in this case disposed laterally below the sample well 120. In some cases, the conjugate pad 103 may be secured to the back card 102. The conjugate pad 103 may be any suitable material that allows for fluid flow by material such as fibers (including fiberglass), polyester, or other materials that provide for fluid flow through the conjugate pad 103. In this exemplary implementation, the conjugate pad 103 includes an analyte-specific conjugate 200 attached to the sample receiving zone 121. An embodiment of the analyte-specific conjugate 200 may be referred to as a "first conjugate" as described in this disclosure. The analyte-specific conjugate 200 is configured to solubilize when a fluid is received at the sample receiving zone 121. As described below in connection with Figure 3, the analyte-specific conjugate 200 includes a first label 210 (such as a sensing molecule), a first binding partner 230, and an agent 220 that specifically binds to an analyte of interest 221 (if present in the sample). Thus, the analyte-specific conjugate 200 is configured to specifically bind to an analyte of interest (if present) in a sample received at the sample receiving zone.

[0028] In one example, the analyte-specific conjugate 200 is placed on or within the sample receiving zone 121. In another example, the analyte-specific conjugate 200 is placed on or within a first conjugate zone located downstream of the sample receiving zone 121 such that the sample (and any analyte of interest, if present) added to the sample receiving zone 121 flows through the first conjugate zone and interacts with the analyte-specific conjugate 200. The analyte-specific conjugate 200 can be placed on or within the assay testing device 101 using any suitable method including, for example, depositing, spraying, soaking, soaking, pouring, or injecting the analyte-specific conjugate on or within the sample receiving zone 121. For example, the analyte-specific conjugate can be deposited by preparing a solution having the analyte-specific conjugate and spraying the solution with an air jet technique. In another example, the analyte-specific conjugate may be prepared in a solution and applied by injecting the solution, spraying the solution, formulating the solution as a powder or gel that is placed or rubbed onto the test strip, or in any other suitable manner.

[0029] The analyte-specific conjugate 200 may be provided in any suitable amount at the sample receiving zone 121 (or other suitable location) of the assay test strip 101. Advantageously, embodiments of the present disclosure can detect the presence and amount of low concentrations of an analyte of interest using certain types of analyte-specific conjugates 200 and amounts typical of conventional lateral flow sandwich assays. In some embodiments, the analyte-specific conjugate is deposited in an amount ranging from about 0.1-20 μL per test strip.

[0030] An embodiment of the system, device, and method described in this disclosure includes a signal amplification conjugate 250. An embodiment of the signal amplification conjugate 250 may be referred to as a "second conjugate" as described in this disclosure. As described below in connection with FIG. 3, the signal amplification conjugate 250 includes a second label 211 and a second binding partner 231. The second binding partner 231 is configured to specifically bind to the first binding partner 230 of the analyte-specific conjugate 200. The signal amplification conjugate 250 is present or added at a location upstream of the analyte-specific conjugate 200. In one example described in connection with FIG. 2, the signal amplification conjugate 250 is added to the assay test strip 101 during the manufacturing process. In another example, the signal amplification conjugate 250 is added to the assay test strip 101 by an operator during a test event. It will be understood that embodiments of the present disclosure are not limited by the manner in which the signal amplification conjugate 250 is introduced into the lateral flow assay, and other examples besides those described herein are suitable. In one example shown in FIG. 2, the signal amplification conjugate is placed on or within the buffer receiving zone 111. In another example, the signal amplification conjugate 250 is placed on or within a second conjugate zone located downstream of the buffer receiving zone 111 and upstream of the sample receiving zone 121 such that the sample (and any analyte of interest, if present) added to the sample receiving zone 121 does not interact with the signal amplification conjugate 250 in the second conjugate zone. This spatial orientation also ensures that the buffer added to the buffer receiving zone 111 flows downstream through the second conjugate zone and solubilizes the signal amplification conjugate 250. Although the non-limiting implementation of FIG. 2 does not use a sample solution to rehydrate the signal amplification conjugate 250, it will be understood that other implementations are suitable. For example, another implementation of the present disclosure may use a single solution (such as a sample solution) to rehydrate both the analyte specific conjugate 200 and the signal amplification conjugate 250. In this case, the sample solutions can be applied at different times to ensure that the signal amplification conjugate 250 migrates down the flow path to the detection zone of the test strip after the analyte-specific conjugate 200 migrates down the flow path to the detection zone.

[0031] The signal amplification conjugate 250 can be placed on or within the assay test device using any suitable method including, for example, depositing, spraying, soaking, pouring, or injecting the signal amplification conjugate 250 onto or within the buffer receiving zone 111 (or other suitable location). For example, the signal amplification conjugate 250 can be deposited by preparing a solution having the signal amplification conjugate 250 and spraying the solution with an air jet technique. In another example, the signal amplification conjugate 250 may be deposited by preparing in solution, pouring the solution, spraying the solution, formulating the solution as a powder or gel that is placed or rubbed onto the test strip, or in any other suitable manner.

[0032] It will be appreciated that the signal amplification conjugate 250 can be added to the assay test strip in an area other than the buffer receiving zone 111. For example, in one non-limiting embodiment, the lateral flow device 100 does not include a separate or dedicated location, such as a buffer well or buffer receiving zone, for receiving the signal amplification conjugate 250 on the assay test strip 101. The signal amplification conjugate 250 can be added to the assay test strip 101 at any suitable location after the analyte-specific conjugate 200 is solubilized in the sample receiving zone 121 and migrates to the detection zone 131. Embodiments of the signal amplification conjugate 250 of the present disclosure can be provided in any suitable amount in the buffer receiving zone 111 (or other suitable location) of the assay test strip 101. In some embodiments, the signal amplification conjugate 250 is applied in an amount ranging from about 0.1 to 20 μL per test strip. In some embodiments, the signal amplification conjugate 250 is applied to the assay test strip 101 in an amount of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 μL per test strip.

[0033] The signal amplification conjugate 250 is placed or added to the assay test strip 101 upstream of the location where the analyte specific conjugate 200 is placed or added to the assay test strip 101. The signal amplification conjugate 250 and the analyte specific conjugate 200 can be placed on the test strip at the same time or at different times during the process of making the assay test strip 101 or by an operator performing a test event using the assay test strip 101. In one non-limiting example, both the signal amplification conjugate 250 and the analyte specific conjugate 200 are added to the assay test strip 101 at the same time or substantially the same time, but at different locations, e.g., by introducing or attaching both the signal amplification conjugate and the analyte specific conjugate to the test strip at the same time or at about the same time. In this example, the analyte specific conjugate 200 is added or placed on the assay test strip 101 downstream of the location where the signal amplification conjugate 250 is added or placed. This spatial orientation minimizes interactions between the conjugates before the analyte-specific conjugate migrates to and is bound at the detection zone 131. In another non-limiting example, the signal amplification conjugate 250 is added to the assay test strip 101 before or after adding the analyte-specific conjugate 200, using any suitable method or technique, including but not limited to those described herein, at any suitable location. For example, the signal amplification conjugate 250 may be added at the same location, or substantially the same location, where the analyte-specific conjugate 200 was originally added, if the signal amplification conjugate 250 is added after the analyte-specific conjugate 200 has migrated to and is bound at the detection zone 131.

[0034] In some embodiments, the lateral flow device 100 does not include a separate or dedicated location such as a buffer well or buffer receiving zone, but includes the signal amplification conjugate 250 prior to a testing event using the assay test strip 101. Instead, the signal amplification conjugate 250 is introduced into the assay test strip 101 by an operator during a testing event. For example, the signal amplification conjugate 250 can be introduced into the assay test strip after a sample is introduced into the assay test strip. In particular, the sample is first placed in the sample receiving zone, and the sample is allowed to migrate through the test assay strip for a suitable time. The time may be sufficient for the analyte-specific conjugate 200 to solubilize, form a binding interaction with the analyte of interest in the sample (if present), migrate to the detection zone, and form a binding interaction with the capture agent immobilized at the detection zone. After incubation for a suitable time, a solution containing the signal amplification conjugate 250 is introduced into the lateral flow device 100. The signal amplification conjugate 250 then migrates through the assay test strip 101 to the detection zone 131.

[0035] The delay time before adding the sample and signal amplification conjugate 250 to the assay test strip 101 can be adjusted based on a variety of parameters including, but not limited to, the characteristics of the analyte of interest, the fluid containing or suspected to contain the analyte of interest, the analyte specific conjugate 200, the signal amplification conjugate 250, and the material properties of the assay test strip 101. Examples of delay times include, but are not limited to, 5 seconds, 10 seconds, 15 seconds, 20 seconds, 25 seconds, 30 seconds, 35 seconds, 40 seconds, 45 seconds, 50 seconds, 55 seconds, 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 12 minutes, and 15 minutes. Thus, in this example, the signal amplification conjugate 250 is not present in the assay test strip 101 at the start of the test event. Thus, embodiments of the present disclosure for amplifying the signal of an analyte present at low concentrations, such as concentrations below the limit of detection, can be accomplished using signal amplification conjugate 250 in a variety of ways, including preparing a test strip with signal amplification conjugate 250 present or adding signal amplification conjugate 250 in a later step.

[0036] The embodiments of the systems, devices and methods described in the present disclosure can detect an analyte of interest very quickly, with the total time from the start of the test event (defined as the time when the sample is applied to the test strip) to the end of the test event (defined as the time when the measurement system detects the signal, if any, generated at the detection zone) being, but not limited to, 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 12 minutes and 15 minutes. 3 shows a schematic diagram of an exemplary embodiment of the system, device and method described in the present disclosure. Without being bound to any particular theory, the process by which the analyte-specific conjugate 200 binds to the analyte of interest 221, the capture agent 240 immobilized in the capture zone 242, and the signal amplification conjugate 250 is now illustrated with reference to FIG. 3, although it will be understood that the present disclosure is not limited to the schematic diagram of FIG.

[0037] The analyte-specific conjugate 200 includes a first label 210, a first binding partner 230, and an agent 220 that specifically binds to the analyte of interest 221 (if present in the sample). The agent 220 configured to specifically bind to the analyte of interest 221 may include an antibody or antibody binding fragment that specifically binds to the analyte of interest 221. The analyte-specific conjugate 200 is attached or added to the sample receiving zone 121 (or any other suitable location) of the assay test strip 101, for example, using the methods described above in connection with FIG. 2. The sample is added to the assay test strip 101, for example, at the sample receiving zone 121. The analyte-specific conjugate 200 solubilizes in the sample, and the agent 220 specifically binds to the analyte of interest 221, if present in the sample, forming an analyte-agent-first label complex 225. The complex 225 flows through the assay test strip 101 to the detection zone 131, which includes an immobilized capture agent 240 configured to specifically bind to the analyte of interest 221. The complex 225 is captured at the detection zone 131, as shown in FIG.

[0038] After a suitable time for the complex 225 to migrate and become captured at the detection zone 131, a signal amplification conjugate 250 as described herein is migrated along the assay test strip 101 downstream of the detection zone 131. The signal amplification conjugate 250 includes a second label 211 and a second binding partner 231. In one non-limiting implementation, the signal amplification conjugate 250 is present in the assay test strip 101 before the sample is added (attached in any suitable manner, including those described above in connection with FIG. 2) and moved downstream of the detection zone 131 by applying a buffer to the signal amplification conjugate 250. In this implementation, the previously attached signal amplification conjugate 250 is attached upstream of the sample receiving zone 121, e.g., the buffer receiving zone 111, which is located upstream of the sample receiving zone 121. This spatial orientation of the signal amplification conjugate 250 in the buffer receiving zone 111 upstream of the analyte specific conjugate 200 in the sample receiving zone 121 ensures that addition of a sample to the sample receiving zone 121 solubilizes and renders mobile the analyte specific conjugate 200, but not the signal amplification conjugate 250. In another non-limiting implementation, the signal amplification conjugate 250 is added to the assay test strip 101 after a suitable time has elapsed following addition of a sample to the sample receiving zone. In this implementation, the buffer containing the signal amplification conjugate 250 may be added to the assay test strip 101 at the buffer receiving zone 111 (if present), the sample receiving zone 121, or any other suitable location on the assay test strip 101.

[0039] In both of these implementations, embodiments of the present disclosure allow the analyte-specific conjugate 200 to migrate to the detection zone 131 and bind to the capture agent 240 before being exposed to the signal amplification conjugate 250 and forming a binding interaction. Embodiments of the present disclosure advantageously allow the timing of the release of the signal amplification conjugate 250 to be tailored to the characteristics of the lateral flow assay, and to activate the release only when buffer is added to the system (either to the buffer receiving zone 111 containing the signal amplification conjugate 250, or to any suitable location if the buffer itself contains the signal amplification conjugate 250). These embodiments of the present disclosure also advantageously prevent interactions between the analyte-specific conjugate 200 and the signal amplification conjugate 250 from occurring in locations on the assay test strip 101 where they are not desired, primarily locations upstream of the detection zone 131. Thus, embodiments of the present disclosure that can time the release of the signal amplification conjugate 250 to an optimal time (after a sufficient amount of the analyte-specific conjugate 200 has migrated to and bound to the detection zone 131) advantageously maximize the occurrence of binding interactions between the analyte-specific conjugate 200 present in the detection zone (whether bound to the capture agent 240 or not) and the signal-amplification conjugate 250 in the optimal location, i.e., the detection zone 131. This causes the signal generated by the conjugates 200, 250 in the detection zone to aggregate and increase to a level above the detection threshold.

[0040] After a buffer is added to the assay test strip 101 to either directly introduce the signal amplification conjugate 250 into the system or to solubilize the signal amplification conjugate 250 already present in the system, a second series of binding events occurs due to the properties of the signal amplification conjugate 250 of the present disclosure. As described above, the second binding partner 231 specifically binds to the first binding partner 230 of the analyte-specific conjugate 200. Without being bound to any particular theory, it is believed that when the signal amplification conjugate 250 flows through the assay test strip 101 to the detection zone 131, the second binding partner 231 of the signal amplification conjugate 250 specifically binds to the first binding partner 230 of the complex 225 bound to the capture agent 240, thereby capturing the signal-amplification conjugate 250 at the detection zone 131. The second label 211 of the just-bound signal amplification conjugate 250 generates a signal at the detection zone. In this manner, the signal from a single analyte-specific conjugate 200 bound to the detection zone is amplified. In some embodiments, a single analyte-specific conjugate 200 of a complex 225 binds to multiple signal amplification conjugates 250 and, as such, contributes to the signal generated by a single analyte-specific conjugate 200 of a complex 225. In some embodiments of the present disclosure, even this first level of binding interaction between a complex 225 and one or more signal amplification conjugates 250 is sufficient to increase the signal generated at the detection zone above a threshold detection level.

[0041] Advantageously, embodiments of the present disclosure can generate a higher level of signal amplification than that allowed by the first level of binding interaction alone. In embodiments of the systems, devices and methods described herein, the amplification of the signal generated at the detection zone is further enhanced by the ability of the just bound signal amplification conjugate 250 to bind to the residual analyte-specific conjugate 200 present at the detection zone but not bound to the capture agent 240. This residual analyte-specific conjugate 200 may normally pass through the detection zone 131 or remain diffusely scattered at the detection zone in a typical lateral flow assay. In the presence of the signal amplification conjugate 250 described in the present disclosure, this residual analyte-specific conjugate 200 can bind to the scaffold of the conjugate retained at the detection zone 131 via the complex 225 and further contribute to the agglutination signal generated at the detection zone 131. The signal generated by embodiments of the present disclosure can increase in intensity exponentially. Thus, in some embodiments, the intensity of the signal generated at detection zone 131 can be increased by amplifying the signal by an amount between 2 and 100 fold, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, or 100 fold. It will be understood that the present disclosure is not limited to these exemplary levels of amplification, and that other levels of amplification are possible with embodiments of the present disclosure.

[0042] Advantageously, the aforementioned chain reaction of binding events can occur even in the presence of very small amounts of the analyte of interest in the sample. Without being bound to any particular theory, it is believed that the remaining analyte-specific conjugate 200 can form a binding interaction with the signal amplification conjugate 250 regardless of whether the remaining analyte-specific conjugate 200 binds to an analyte in the sample. In other words, the binding interaction subsequent to the first interaction between the complex 225 and the signal amplification conjugate 250 relies on this first interaction to ensure a chain reaction of binding events in a localized area (detection zone), but does not rely on additional analytes of interest to form a scaffold of pairs of binding conjugates 200, 250 that amplify the signal generated by the complex 225. An advantage of the present disclosure is also that the absence of signal at the detection zone 131 can be reliably correlated with the presence of the analyte of interest in the sample. In the absence of the analyte of interest in the sample, the complex 225 does not form and does not bind to the capture agent 240 at the detection zone 131. In the absence of a binding event, the signal amplification conjugate 250 does not bind at the detection zone 131 and passes through the detection zone 131 to the absorbent pad 151.

[0043] As used herein, buffer refers to a solution used in lateral flow assays that does not interfere with binding interactions, does not denature the analyte of interest and other components of the device, and maintains neutrality for the purpose of allowing components to flow to the test strip.Various buffers are known, and any of a variety of buffers can be used for the particular analytes, compounds, and components used in the lateral flow assays described herein.In some embodiments, the buffer is phosphate buffered saline (PBS). The embodiments of the present disclosure have been described in connection with a buffer receiving zone located upstream of the sample receiving zone, and a chase buffer added to the buffer containing the signal amplification conjugate added to any suitable location of the assay test strip after the sample is added. However, it will be understood that other methods of adding or releasing the buffer to the system are suitable and can be used with the embodiments of the present disclosure. For example, the chase buffer can be prepackaged in a small bag or other suitable structure and incorporated into the assay test strip upstream of the attached signal amplification conjugate and the sample receiving well of the assay test strip. The chase buffer can be released by rupturing the small bag using any suitable mechanism at a suitable time after the sample is added to the assay test strip.

[0044] In some embodiments, the signal amplification conjugate 250 does not bind to other conjugates (such as the analyte-specific conjugate 200) until it reaches the detection zone 131. In some embodiments, binding of the signal amplification conjugate 250 to other conjugates results in precipitation of the bound conjugate, causing a smear of the deposited label through the test strip, thereby interfering with or confusing the results. As previously mentioned, embodiments of the present disclosure include features that prevent or minimize this precipitation of bound conjugates upstream of the detection zone 131. These features ensure that the signal amplification conjugate 250 remains solubilized in solution and does not bind to the analyte-specific conjugate 200 before it reaches the analyte-specific conjugate 200 of the captured complex 225 at the detection zone 131. In one example, an embodiment of the present disclosure includes attaching a signal amplification conjugate 250 to the assay test strip 101 upstream of the analyte-specific conjugate 200 at the sample receiving zone 121 and solubilizing the signal amplification conjugate 250 only after the analyte-specific conjugate has first had an opportunity to flow through the lateral flow device to the detection zone 131. In another example, an embodiment of the present disclosure includes adding the signal amplification conjugate 250 to a buffer applied to the assay test strip 101 only after the analyte-specific conjugate 200 has first had an opportunity to flow through the lateral flow device to the detection zone 131.

[0045] The first label 210 of the analyte-specific conjugate 200 can be the same label as the second label 211 of the signal amplification conjugate 250. In one non-limiting example, the first label 210 and the second label 211 can be colloidal gold labels. The colloidal gold labels can include gold nanoparticles. The first label 210 and the second label 211 can include any suitable label that can provide a detectable signal. Thus, in some embodiments, the first label 210 and the second label 211 are enzymes, colloidal gold particles (also referred to as metal nanoparticles such as gold or silver nanoparticles), colored latex particles, radioisotopes, cofactors, ligands, chemiluminescent or fluorescent substances, protein-adsorbed silver particles, protein-adsorbed iron particles, protein-adsorbed copper particles, protein-adsorbed selenium particles, protein-adsorbed sulfur particles, protein-adsorbed tellurium particles, tellurium carbon particles, or protein-adsorbed dye sacs or any other suitable labels.

[0046] As mentioned above, the agent 220 is an agent that specifically binds to the analyte of interest 221 and may include an antibody or antibody binding fragment that specifically binds to the analyte of interest 221. Thus, the agent 220 may be an anti-analyte antibody. The first binding partner 230 of the analyte-specific conjugate 200 specifically binds to the second binding partner 231 of the signal amplification conjugate 250, and thus the first and second binding partners 230, 231 constitute a binding pair. The binding pair may include, for example, a binding pair selected from the group consisting of antigen / antibody, hapten / antibody, hormone / receptor, nucleic acid strand / complementary nucleic acid strand, substrate / enzyme, inhibitor / enzyme, carbohydrate / lectin, biotin / avidin, receptor / ligand, or virus / cell receptor. In one non-limiting example, the first binding partner 230 is avidin (or a derivative or analog thereof) and the second binding partner 231 is biotin (or a derivative or analog thereof). For example, the analyte-specific conjugate 200 can be biotinylated and the signal amplification conjugate 250 can include an anti-biotin antibody or a streptavidin binding partner. In another non-limiting example, the binding pair is an antigen / antibody, such as a peptide and an antibody. In some embodiments, the peptide is a decapeptide. In a further non-limiting example, the binding pair is doxorubicin and anti-doxorubicin. In a further non-limiting example, the binding pair is methotrexate and anti-methotrexate. In yet another non-limiting example, the binding pair is FITC and an anti-FITC antibody. It will be understood that embodiments of the present disclosure can use any suitable first binding partner 230 that specifically binds to the second binding partner 231 and is not limited to the aforementioned examples.

[0047] An advantage of the embodiments of the present disclosure is that the second binding partner 231 of the signal amplification conjugate 240 can be selected to specifically bind to the first binding partner 230 of the analyte-specific conjugate 200 without interfering with the binding of the analyte of interest 221 to the analyte-specific antibody of the analyte-specific conjugate 200. In one example, a different protein / peptide can be co-conjugated with the analyte-specific antibody on the first label 210 to form the analyte-specific conjugate 200. In another example, another protein / peptide can be first biotinylated and then co-conjugated with the analyte-specific conjugate on the first label 210 to form the analyte-specific conjugate 200. In a further example, a small molecule such as biotin is added to the analyte-specific antibody and later bound to the first label 210 of the analyte-specific conjugate 200, and the signal amplification conjugate 250 includes a small molecule specific binding protein / antibody. In this example, the small molecule added to the analyte-specific antibody is selected so as not to interfere with the binding of the analyte to the analyte-specific antibody in the analyte-specific conjugate 200. In yet another example, rather than biotin, a protein / peptide can bind to another antibody or another molecule where a binding protein is present. The added protein / peptide, biotin or other molecule attached to the first label 210 can thus provide a binding site for an antibody to this protein / peptide, biotin or other molecule in the signal amplification conjugate 250 without interfering with the analyte-specific binding interaction between the analyte of interest 221 and the analyte-specific antibody attached to the first label 210.

[0048] In some embodiments, the lateral flow device includes one or more control zones. The control zone may be in the detection zone or may be separate from the detection zone. In some embodiments, the control zone may be a positive control zone and may include a small molecule bound to a protein such as bovine serum albumin (BSA). A positive control labeled antibody that specifically binds to the small molecule may be attached to the conjugate pad. When the positive control labeled antibody is rehydrated in the liquid sample, it flows to the positive control zone, binds to the small molecule, and forms a half sandwich. In some embodiments, the positive control zone includes an immobilized capture material that specifically binds to the analyte-specific conjugate, and the analyte-specific conjugate that does not bind to the analyte of interest passes through the detection zone (test line) and specifically binds to the immobilized capture material in the control line, generating a signal indicative of proper functioning of the lateral flow device. It will be understood that any suitable control zone may be implemented in the embodiments of the present disclosure. The reader and data analyzer embodiments disclosed herein can process the signal measurements obtained from the control zone to correct the signal measured in the detection zone or to alert the operator that the test is invalid.

[0049] As used herein, "analyte" generally refers to a substance to be detected. In some embodiments, the analyte is one that is found in a sample at low concentrations, such as concentrations below the detection limit of a measurement system. Some analytes are normally present in a sample at high concentrations, but may be present in a particular sample under test at low concentrations due to a particular disorder, phase of the disorder, or sample processing. For example, an analyte may be present in a sample at low concentrations at an early stage of a disease or disorder, followed by a peak stage of the disease or disorder. It will be understood that embodiments of the present disclosure are applicable to lateral flow assays that measure any analyte that is or is likely to be present in a sample in low amounts, or where the sensitivity of measuring such analytes is low.

[0050] Analytes may include antigenic substances, haptens, antibodies, and combinations thereof. Analytes include, but are not limited to, toxins, organic compounds, proteins, peptides, microorganisms, amino acids, nucleic acids, hormones, steroids, vitamins, drugs (including therapeutically administered drugs and illicitly administered drugs), drug intermediates or by-products, bacteria, virus particles, and metabolites or antibodies of any of the foregoing substances. In some embodiments, the analyte of interest is an influenza virus, such as influenza A, influenza B, or influenza C virus. Additional analytes may be included for organisms or environmental substances of interest.

[0051] In some embodiments, a sample may contain one or more analytes of interest, and thus the lateral flow device may be configured to detect one or more analytes of interest. To detect one or more analytes of interest, the lateral flow device of the present disclosure may include one or more analyte-specific conjugates 200, each analyte-specific conjugate 250 specifically binding to an analyte of interest. Thus, for example, for a desired number of analytes of interest present or suspected to be present in a sample, a first analyte-specific conjugate 200A specifically binds to a first analyte of interest 221A, a second analyte-specific conjugate 200B specifically binds to a second analyte of interest 221B, a third analyte-specific conjugate 200C specifically binds to a third analyte of interest 221C, and so on. In some embodiments, each analyte-specific conjugate that specifically binds to an analyte of interest does not specifically bind to any other analytes of interest. Further, in some embodiments, each analyte-specific conjugate may have the same label or a different label than each other analyte-specific conjugate. So, for example, each analyte-specific conjugate may include a unique label that is different from any other label of the analyte-specific conjugate. Furthermore, when more than one analyte of interest is present, the lateral flow device may include one or more capture lines, each capture line including an immobilized capture material that specifically binds to one particular analyte of interest. For example, for a desired number of analytes of interest to be analyzed in a test sample, a first capture material 240A immobilized in capture zone 242A specifically binds to a first analyte of interest 221A, a second capture material 240B immobilized in capture zone 242B specifically binds to a second analyte of interest 221B, and a third capture material 242C immobilized in capture zone 242C specifically binds to a third analyte of interest 221C. In some embodiments in which the lateral flow device is configured to measure one or more analytes of interest, the device further comprises a signal amplification conjugate 250. The signal amplification conjugate 250 may comprise one binding partner of a binding pair that specifically binds to another binding partner of the binding pair. In some embodiments, the signal amplification conjugate binds to a first analyte-specific conjugate, a second analyte-specific conjugate, a third analyte-specific conjugate, etc. for a desired number of analytes of interest, thereby amplifying the signal for each of the analytes of interest. In some embodiments, the signal amplification conjugate binds to one, two, three or more analyte-specific conjugates, thereby amplifying the signal only for a desired number of analytes, e.g., only for analytes of interest known or suspected to be present in low concentrations in the sample.

[0052] It should be understood that analytes of interest are often present in a sample at various concentrations, and thus signal amplification may not be required for each analyte of interest, but only for those analytes of interest known or suspected to be present at low concentrations, such as concentrations below the detection limit of the measurement system. Thus, in some embodiments, a first analyte-specific conjugate that specifically binds to a first analyte present at a low concentration includes a binding partner, and a second analyte-specific conjugate that specifically binds to a second analyte present at a concentration above the detection limit does not include a binding partner, whereby the signal amplification conjugate binds to the first analyte-specific conjugate but not to the second analyte-specific conjugate, thereby amplifying the signal of the first analyte of interest. Various iterations of the present disclosure may be implemented, for example, by amplifying any desired signal, including signals below the detection limit of the measurement system. The following non-limiting examples illustrate features of the lateral flow devices, test systems and methods described herein and are not intended to limit the scope of the disclosure in any way.

[0053] Example 1 Preparation of the Lateral Flow Assay According to the Invention The following example describes the preparation of a lateral flow assay according to the present disclosure for measuring an analyte present in a sample at low concentrations. In this non-limiting example, the analyte of interest is Influenza A ("Flu A"). Test strips were prepared with a conjugate pad having a sample receiving zone and a buffer receiving zone. The analyte-specific conjugate was prepared in a solution, and the solution was sprayed by air jet deposition onto the sample receiving zone. Briefly, anti-Flu A antibody and biotin were incubated with gold nanoparticles to form the analyte-specific conjugate. The analyte-specific conjugate was deposited onto the conjugate pad at the sample receiving zone in an amount of 7 μL / test strip by spraying a solution containing the analyte-specific conjugate with an air jet. The conjugate pad was heated to dry the analyte-specific conjugate onto the conjugate pad. The amount of anti-Flu A antibody deposited onto the conjugate pad used to formulate the analyte-specific conjugate was approximately 260 ng per test strip.

[0054] The signal amplification conjugate was prepared in a solution and the solution was sprayed by air jet deposition into the buffer receiving zone. Briefly, anti-biotin was incubated with gold nanoparticles to form the signal amplification conjugate. The signal amplification conjugate was deposited in an amount of 2 μL / test strip onto the conjugate pad at the buffer receiving zone by spraying a solution containing the signal amplification conjugate with an air jet. The conjugate pad was heated to dry the signal amplification conjugate onto the conjugate pad. The amount of anti-biotin antibody deposited onto the conjugate pad used to formulate the signal amplification conjugate was approximately 74 ng per test strip. Additionally, test strips were prepared having a detection zone, which included an immobilized capture agent that specifically binds Flu A. In this example, anti-Flu A antibody was attached to the detection zone in an amount of 2.4 mg / mL at 0.75 μL / cm. In this example, the detection zone also included a positive control capture zone. The positive control capture zone was prepared to ensure proper functioning of the assay. In this example, the positive control capture zone included immobilized bovine serum albumin derivatized with anti-biotin (BSA-anti-biotin). The immobilized BSA-biotin captured the signal amplification conjugate present on the test strip rehydrated with buffer and migrated to the positive control zone, indicating proper functioning of the assay. The signal amplification conjugate was captured at the positive control line and the positive control signal indicated proper functioning of the assay. The test strip was placed in a lateral flow device having a housing to hold the test strip. The lateral flow device included a buffer well positioned above a buffer receiving zone, a sample well positioned above a sample receiving zone, and a read window positioned above a detection zone, as shown in FIG.

[0055] Example 2 Amplification of signals of low concentration analytes The following example demonstrates the use of the lateral flow assay described in Example 1 to detect low concentrations of Flu A in a sample. The lateral flow assay as prepared in Example 1 was contacted with a sample containing a low concentration of Flu A. In this non-limiting example, the Flu A antigen was a dilution of recombinant Flu A nucleoprotein expressed in E. coli and applied as a crude cell lysate. As a control, a lateral flow assay as prepared in Example 1 was used lacking the signal amplification conjugate. A sample with Flu A was added to the sample well of the lateral flow device and to the control lateral flow device. The signal generated was measured at various time points as shown in FIG. 4 and Table 1.

[0056] [Table 1]

[0057] Samples that did not contain the analyte of interest were also applied to the lateral flow assay prepared with various amounts of the signal amplification conjugate described in this disclosure. In particular, amounts of 0.5, 1, 1.5, and 3 μL of the signal amplification conjugate were applied to the test strips and compared with the control strips, and readings were obtained at 10 minutes and 20 minutes. The results are shown in Table 2, and were measured in duplicate at each time point. Samples that did not contain the analyte of interest were applied to the assay test strips to verify that no signal was generated at the test line when the analyte of interest was not present in the sample. As shown in Table 2 below, the signal at the test line remained negative (0 AU or substantially 0 AU signal intensity was measured at the test line) for all samples that did not contain the analyte of interest. Therefore, any signal below 1 AU can be considered equivalent to a measurement of 0 AU as system noise. Furthermore, as shown in Table 2 below, the intensity of the system noise measurement did not increase with increasing amounts of signal amplification conjugate. Without being bound to any particular theory, it is believed that the signal amplification conjugate does not amplify a signal in the absence of the analyte of interest because there is no initial signal to amplify (in other words, with the absence of analyte in the sample, no sandwich structure forms at the test line and therefore no sandwich structure is present to generate a signal that is amplified by the signal amplification conjugate).

[0058] [Table 2]

[0059] Finally, the amount of Flu A was varied in the samples before being placed in the lateral flow device. Specifically, samples were prepared with Flu A in amounts of 0%, 0.04%, 0.1%, 0.2% and 0.5% (expressed as a percentage of the antigen concentration in the sample) and the samples were applied to a lateral flow device without any signal amplification conjugate and to a control lateral flow device. Signal intensity was read at 10 and 20 minutes. The results are shown in Figure 5 and Table 3.

[0060] [Table 3]

[0061] Advantageously, the lateral flow assay described in the present disclosure amplifies the signal of an analyte present in a sample at low concentrations, such as below the detection limit, thereby allowing reliable measurement of the analyte present in a sample at low concentrations. In addition to determining the presence of an analyte of interest in a sample, embodiments of the present disclosure can also be used to quantify the amount of an analyte of interest present in a sample. For example, a solution having a known amount of an analyte of interest can be applied to an assay test strip prepared according to an embodiment of the present disclosure. A measurement system can measure the intensity of the signal generated by the test strip, and a dose-response curve can be generated using this data. After performing a test event using a test strip prepared according to an embodiment of the present disclosure, the measurement system can measure the signal generated by the test strip and compare the test signal to the signal plotted in the dose-response curve to determine the amount of the analyte of interest in the test sample. It will be understood that other methods of quantifying the amount of an analyte of interest are possible using embodiments of the present disclosure.

[0062] Methods for detecting an analyte of interest in a sample using the lateral flow assays described herein 6 shows an exemplary method 600 for detecting an analyte of interest in a sample at low concentrations using a lateral flow assay as described herein. The method 600 begins at step 605, where a lateral flow assay as described herein is provided. In step 610, a sample is applied to a sample well of a lateral flow device. In some embodiments, applying the sample to the sample well comprises contacting the sample with a lateral flow assay. The sample can be contacted with the lateral flow assay by introducing the sample to the sample well by external application, as with a dropper or other applicator. In some embodiments, the sample reservoir may be directly immersed in the sample, such as when a test strip is immersed in a container that holds the sample. In some embodiments, the sample may be poured, dipped, sprayed, placed, or contacted with the sample reservoir. The method then moves to step 615, where application of the sample at the sample well solubilizes an analyte-specific conjugate ("first conjugate") present at the sample receiving zone or a first conjugate zone downstream of the sample receiving zone. The analyte-specific conjugate comprises a first label, a first binding partner, and an agent that specifically binds to the analyte of interest. As previously mentioned, depending on the number of analytes to be analyzed, the device may include a second analyte-specific conjugate comprising a label, a binding partner, and an agent that specifically binds to a second analyte of interest, and the device may include a third analyte-specific conjugate or additional analyte-specific conjugates comprising a label, a binding partner, and an agent that specifically binds to a third analyte of interest. In some embodiments, the analyte-specific conjugate may not include a binding partner, as a particular analyte of interest may not require amplification due to the expected or general concentration of the particular analyte of interest in the sample.

[0063] The analyte-specific conjugate (or optionally one or more analyte-specific conjugates) can be integrated into the sample receiving zone by physical or chemical bonds. After a sample is added to the sample well, the sample solubilizes the analyte-specific conjugate, releasing the bonds that hold the analyte-specific conjugate to the conjugate pad. Moving next to step 620, the analyte of interest (if present in the sample) is labeled with an analyte-specific conjugate. The analyte-specific conjugate, if present in the sample, binds to the analyte of interest and forms a complex. It will be appreciated that steps 615 and 620 can occur substantially simultaneously. The method then proceeds to step 625, where the complex travels along the fluid flow path of the assay test device and binds to the immobilized capture material at the detection zone of the lateral flow assay, forming a sandwich structure. It will also be appreciated that the practice of the present disclosure may form a sandwich structure at the detection zone in many different ways. For example, steps 615, 620 and 625 may be replaced with step 615A, where the analyte of interest and the analyte-specific conjugate flow separately to the detection zone, the analyte of interest binds to the immobilized capture material at the detection zone, and then the analyte-specific conjugate binds to the just-bound analyte of interest, forming an antibody-analyte-antibody-first label structure, commonly referred to as a sandwich.

[0064] After binding (or forming a sandwich structure) the complex to the immobilized capture material, the method then moves to step 630, where a buffer is applied to the buffer well (or other suitable location) of the device. In step 635, the buffer solubilizes the signal amplification conjugate ("second conjugate") that is present or located downstream of the buffer receiving zone. The signal amplification conjugate includes a second label and a second binding partner that specifically binds to the first binding partner of the analyte-specific conjugate. The signal amplification conjugate may be integrated into the buffer receiving zone (or other suitable location) by physical or chemical binding. After the buffer is added to the buffer well, the buffer solubilizes the signal-amplification conjugate and releases the bonds that hold the signal amplification conjugate to the conjugate pad of the buffer receiving zone (or other suitable location). It will be understood that steps 630 and 635 may be replaced by alternative methods to add the signal amplification conjugate to the lateral flow assay.

[0065] The method then proceeds to step 640, where the signal amplification conjugate flows with the buffer to the detection zone. At the detection zone, the second binding partner forms a binding pair with the first binding partner of the analyte-specific conjugate of the complex bound to the capture substance at the detection zone. As described above, the first binding interaction between the signal amplification conjugate and the complex bound to the capture substance at the detection zone can amplify the signal generated at the detection zone to a level above a threshold detection level. Thus, in some exemplary implementations, the method then proceeds to step 650, where the amplified signal is detected at the detection zone. The embodiment of the method according to the present disclosure may also include the following binding interactions as described above. A chain reaction of binding events occurs according to the present disclosure, where a series of interactions of the first and second binding pairs accumulates the analyte-specific conjugates and signal amplification conjugates that form at the detection zone. The accumulation of the conjugates at the detection zone amplifies the signal generated at the detection zone, and in some cases, amplifies the signal exponentially. This chain reaction of binding events is shown in step 645 of FIG. 6, where the unbound first conjugates present at the detection zone bind to the signal amplification conjugates that become bound to the complex at the detection zone.

[0066] Moving now to step 650, the method includes detecting a signal generated at the detection zone. The detection zone may include a capture zone that captures each complex (where one or more analytes of interest are detected and / or quantified). For example, the detection zone may include a first capture zone for capturing the first complex, a second capture zone for capturing the second complex, and a third capture zone for capturing the third complex. The first immobilized capture material at the first capture zone binds to the first analyte (if present) and the first complex. If the first complex binds to the first immobilized capture material at the first capture zone and the signal amplification conjugate binds thereto, a first amplified signal is detected. The first amplified signal may include an optical signal as described herein. The signal generated at the detection zone may be detected using any suitable measurement system in step 650, including, but not limited to, visual inspection of the device and optical detection using an optical reader. The signal detected in step 650 may be correlated to the presence, absence, or amount of the analyte of interest in the sample. In some embodiments, the sample is obtained from a source, including an environmental or biological source. In some embodiments, the sample is suspected of having one or more analytes of interest, including one or more analytes of interest present at low concentrations, such as concentrations below the detection limit of a measurement system. In some embodiments, the sample is suspected of not having any analytes of interest. In some embodiments, the sample is obtained and analyzed to verify the presence or absence of multiple analytes. In some embodiments, the fluid sample is blood or plasma. In some embodiments, the fluid sample is applied in a volume of 50-100 μL. In some embodiments, the signal detected is an optical signal, a fluorescent signal, or a magnetic signal.

[0067] Exemplary Test Systems Including Lateral Flow Assays Described in This Disclosure The lateral flow assay test system described herein may include a lateral flow assay test device (such as, but not limited to, a test strip), a system housing including a port configured to receive all or a portion of the test device, a reader including a light source and a photodetector, a data analyzer, and combinations thereof. The system housing may be made of any one of a wide variety of materials including plastic, metal, or composite materials. The system housing forms a protective enclosure for the components of the diagnostic test system. The system housing also defines a receptacle that mechanically registers the test strip with the reader. The receptacle may be designed to receive any one of a wide variety of different types of test strips. In some embodiments, the system housing is a compact device capable of performing lateral flow assays in a variety of environments including bench, field, home, or facility for domestic, commercial, or environmental applications.

[0068] The reader may include one or more optoelectronic components for optically inspecting the exposed area of ​​the detection zone of the test strip and may detect multiple capture zones in the detection zone. In some implementations, the reader includes at least one light source and at least one photodetector. In some embodiments, the light source may include a semiconductor light emitting diode and the photodetector may include a semiconductor photodiode. Depending on the nature of the label used by the test strip, the light source may be designed to emit light within a particular wavelength range or light having a particular polarization. For example, if the label is a fluorescent label such as a quantum dot, the light source is designed to illuminate the exposed area of ​​the capture zone of the test strip with light in a wavelength range that induces fluorescence emission from the label. Similarly, the photodetector may be designed to selectively capture light from the exposed area of ​​the capture zone. For example, if the label is a fluorescent label, the photodetector is designed to selectively capture light within the wavelength range of the fluorescence emitted by the label or with light of a particular polarization. On the other hand, if the label is a reflective type label, the photodetector is designed to selectively capture light within the wavelength range of the light emitted by the light source. Finally, the photodetector may contain one or more optical filters that define the wavelength range or polarization axis of the captured light. The signal from the label can be detected visually, or by a spectrophotometer that detects color from a chromogenic substrate, 125 The assay can be performed using a radiometer to detect radiation, such as a gamma meter to detect I, or a fluorometer to detect fluorescence in the presence of light of a particular wavelength. If an enzyme-linked assay is used, quantitative analysis of the amount of the analyte of interest can be performed using a spectrophotometer. The lateral flow assays described herein can be automated or performed robotically, and signals from multiple samples can be detected simultaneously, if desired. Furthermore, multiple signals can be detected for multiple analytes of interest, including when the labels for each analyte of interest are the same or different.

[0069] The data analyzer processes the signal measurements obtained by the reader. Generally, the data analyzer can be implemented in any computing or processing environment, including digital electronic circuitry or computer hardware, firmware, or software. In some embodiments, the data analyzer includes a processor (e.g., a microcontroller, a microprocessor, or an ASIC) and an analog-to-digital converter. The data analyzer can be integrated into the housing of the diagnostic test system. In other embodiments, the data analyzer is located in a separate device, such as a computer, that can communicate with the diagnostic test system by wired or wireless connection. The data analyzer can also include circuitry for transferring results by wireless connection to an external device for data analysis or review of the results.

[0070] Generally, the result indicator may include any one of a wide variety of different mechanisms that indicate one or more results of the assay test. In some implementations, the result indicator includes one or more lights (e.g., light emitting diodes) that are activated, for example, to indicate completion of the assay test. In other implementations, the result indicator includes an alphanumeric display (e.g., a two or three character light emitting diode array) to indicate the result of the assay test. The test systems described herein may include a power supply that provides power to the active components of the diagnostic test system, including the reader, data analyzer, and result indicator. Powering may be provided, for example, by a replaceable or rechargeable battery. In other embodiments, the diagnostic test system may be powered by an external host device (e.g., a computer connected by a USB cable).

[0071] Exemplary Lateral Flow Device Features The lateral flow devices described herein include a device housing. The housing of any of the lateral flow devices described herein, including the top housing or the base housing, can be made of any suitable material, including, for example, vinyl, nylon, polyvinyl chloride, polypropylene, polystyrene, polyethylene, polycarbonate, polysulfane, polyester, urethane, or epoxy. The housing can be prepared by any suitable method, including, for example, injection molding, compression molding, transfer molding, blow molding, extrusion molding, foam molding, thermoforming, casting, layer deposition, or printing. The lateral flow devices described herein may include a sample well into which a fluid sample is introduced to a test strip, such as, but not limited to, an immunochromatographic test strip present in the lateral flow device. In one example, the sample may be introduced into the sample well by external application, such as with a dropper or other applicator. The sample may be poured or squeezed into the sample well. In another example, the sample well may be directly immersed in the sample, such as when a test strip is immersed in a container that holds the sample.

[0072] The lateral flow devices described herein may include a buffer well where a buffer is introduced to a test strip, such as, but not limited to, an immunochromatographic test strip present in the lateral flow device. In one example, the buffer may be introduced into the buffer well by external application, such as with a dropper or other applicator. The buffer may be poured or squeezed into the buffer well. In another example, the buffer well may be directly immersed in the buffer, such as when a test strip is immersed in a container that holds the buffer. The lateral flow device described herein may include a solid support or substrate. Suitable solid supports include, but are not limited to, nitrocellulose, walls of wells of reaction trays, multi-well plates, test tubes, polystyrene beads, magnetic beads, membranes and microparticles (such as latex particles). Any suitable porous material with sufficient porosity that can be accessed by analyte-specific conjugates and signal amplification conjugates and has suitable surface affinity for immobilized capture substances can be used in the lateral flow device described herein. For example, the porous structure of nitrocellulose has excellent absorption and absorption qualities for a wide variety of materials, such as immobilized capture substances. Nylon has similar characteristics and is also suitable. Microporous structures are useful as are materials with gel structures in hydrated state.

[0073] Further examples of useful solid supports include natural polymeric carbohydrates and their synthetically modified, cross-linked or substituted derivatives, e.g., agar, agarose, cross-linked alginic acid, substituted and cross-linked guar gum, cellulose esters, especially with nitrile and carboxylic acids, mixed cellulose esters, and cellulose ethers; nitrogen-containing natural polymers such as proteins and derivatives, including cross-linked or modified gelatin; natural hydrocarbon polymers such as latex and rubber; polyethylene, polypropylene, polystyrene, polyvinyl chloride, polyvinyl polyvinyl acetate and their partially hydrolyzed derivatives, polyacrylamide, polymethacrylic acid, copolymers and terpolymers of the foregoing polycondensates, e.g., polyesters, polyamides and polysuccinimides. Synthetic polymers that can be prepared with suitable porous structures, such as vinyl polymers, including other polymers such as urethanes or polyepoxides; porous inorganic materials, such as barium sulfate, calcium sulfate, calcium carbonate, alkali and alkaline earth metal silicates, alkaline earth metal and magnesium sulfates or carbonates, including aluminum and magnesium; and aluminum or silicon oxides, such as clay, alumina, talc, kaolin, zeolites, silica gel or glass, which materials may be used as filters in conjunction with the aforementioned polymeric materials; and mixtures or copolymers of the aforementioned classes, such as graft copolymers obtained by initiating the polymerization of synthetic polymers onto existing natural polymers.

[0074] The lateral flow devices described herein may include a porous solid support, such as nitrocellulose, in the form of a sheet or strip. The thickness of such a sheet or strip may vary over a wide range, for example, about 0.01-0.5 mm, about 0.02-0.45 mm, about 0.05-0.3 mm, about 0.075-0.25 mm, about 0.1-0.2 mm, or about 0.11-0.15 mm. The pore size of such a sheet or strip may vary over a wide range as well, for example, about 0.025-15 μm, more particularly about 0.1-3 μm, although pore size is not intended to be a limiting factor in the selection of the solid support. The flow rate of the solid support, if applicable, may also vary over a wide range, for example, about 12.5-90 sec / cm (i.e., 50-300 sec / 4 cm), about 22.5-62.5 sec / cm (i.e., 90-250 sec / 4 cm), about 25-62.5 sec / cm (i.e., 100-250 sec / 4 cm), about 37.5-62.5 sec / cm (i.e., 150-250 sec / 4 cm), or about 50-62.5 sec / cm (i.e., 200-250 sec / 4 cm). In certain embodiments of the devices described herein, the flow rate is about 35 sec / cm (i.e., 140 sec / 4 cm). In other certain embodiments described herein, the flow rate is about 37.5 sec / cm (i.e., 150 sec / 4 cm).

[0075] The surface of the solid support may be activated by a chemical treatment that results in covalent attachment of the agent (e.g., an immobilized conjugate) to the support. As described below, the solid support may include a conjugate pad. Many other suitable methods may be used to immobilize the agent (e.g., an immobilized capture agent) to the solid support, including, but not limited to, ionic interactions, hydrophobic interactions, covalent interactions, and the like. Except where physically limited, a solid support may be used in any suitable form, such as a film, sheet, strip or plate, or the solid support may be coated or attached or laminated to a suitable inert carrier, such as paper, glass, plastic film or cloth.

[0076] The lateral flow devices described herein can include a conjugate pad, such as a membrane or other type of material that includes a capture agent. The conjugate pad can be cellulose acetate, nitrocellulose, polyamide, polycarbonate, glass fiber, membrane, polyethersulfone, regenerated cellulose (RC), polytetrafluoroethylene (PTFE), polyester (e.g., polyethylene terephthalate), polycarbonate (e.g., 4,4-hydroxy-diphenyl-2,2'-propane), aluminum oxide, mixed cellulose esters (e.g., a mixture of cellulose acetate and nitrocellulose), nylon (e.g., polyamide, hexamethylenediamine, and nylon 66), polypropylene, PVDF, high density polyethylene (HDPE) + nucleating agent "aluminum dibenzoate" (DBS) (e.g., 80u0.024HDPE DBS (Porex)), and HDPE. The lateral flow devices described herein are used for low sensitivity samples, such as samples with low concentrations of analyte or common concentrations of analyte but present in a low volume of sample. "Sensitivity" refers to the proportion of actual positives that are correctly identified as positive (e.g., the proportion of infected, latent or symptomatic subjects that are correctly identified as having a pathology). Sensitivity can be calculated as the number of true positives divided by the sum of the number of true positives and the number of false negatives.

[0077] The lateral flow devices described herein can accurately measure multiple analytes of interest in many different types of samples. Samples can include lesions or cultures obtained from any source, as well as biological and environmental samples. Biological samples can be obtained from animals (including humans) and include fluids, solids, tissues, and gases. Samples can be processed before being applied to the lateral flow devices of the present disclosure. In a first non-limiting example, a whole blood sample can be processed to obtain plasma or serum, and the plasma and serum can be applied to the lateral flow devices described in the present disclosure. In a second non-limiting example, a sample containing cells is processed using one or more sample preparation steps, such as, but not limited to, a cell lysis step to release intracellular proteins for detection. The processed sample can be applied to the lateral flow devices described in the present disclosure. Biological samples include urine, saliva, and blood products such as plasma, serum, etc. Such examples, however, are not considered to be limiting of the types of samples applicable to the present disclosure.

[0078] The lateral flow devices described herein may include a label. The label may take many different forms, including a molecule or composition that is bound or can bind to an analyte, an analyte analog, a detector reagent, or a binding partner that can be detected by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical, or chemical means. Examples of labels include enzymes, colloidal gold particles (also called gold nanoparticles), colored latex particles, radioisotopes, cofactors, ligands, chemiluminescent or fluorescent substances, protein-absorbed silver particles, protein-absorbed iron particles, protein-absorbed copper particles, protein-absorbed selenium particles, protein-absorbed sulfur particles, protein-absorbed tellurium particles, protein-absorbed carbon particles, and protein-bound disacs. Attachment of a compound (e.g., a detector reagent) to the label may be by electrostatic binding or a combination of binding and interactions, such as covalent binding, absorption process, anaerobic and / or chelation, and / or involving a binding group. The term "specific binding partner" or "binding partner" refers to members of a molecular pair that interact by specific, non-covalent interactions that depend on the three-dimensional structures of the molecules involved. Common specific binding partner pairs include antigen / antibody, hapten / antibody, hormone / receptor, nucleic acid strand / complementary nucleic acid strand, substrate / enzyme, inhibitor / enzyme, carbohydrate / lectin, biotin / (strept)avidin, receptor / ligand, or virus / molecule receptor, or various combinations thereof.

[0079] As used herein, the term "immunoglobulin" or "antibody" refers to a protein that binds to a specific antigen. Immunoglobulins include, but are not limited to, polyclonal, monoclonal, chimeric and humanized antibodies, Fab fragments, F(ab')2 fragments, including immunoglobulins of the following classes: IgG, IgA, IgM, IgD, IgE and secretory immunoglobulin (sIg). Immunoglobulins generally contain two identical heavy chains and two light chains. However, the terms "antibody" and "immunoglobulin" also include single chain and two chain antibodies. As used herein, the term antibody refers to the antibody as a whole or any fragment thereof, including binding fragments. Thus, when referring to a labeled antibody that specifically binds to an analyte of interest, the term refers to the labeled antibody or a fragment thereof that specifically binds to the analyte of interest. Similarly, when referring to a capture agent or antibody, the term refers to the capture antibody or a fragment thereof that specifically binds to the analyte of interest. The antibodies in the lateral flow device, test devices and methods described herein may include polyclonal antibodies. Polyclonal antibodies for measuring any analyte of interest disclosed herein include, but are not limited to, antibodies produced from serum by active immunization of one or more of the following: rabbit, goat, sheep, chicken, duck, guinea pig, mouse, donkey, camel, rat and horse. The antibodies in the lateral flow device, test devices and methods described herein may include monoclonal antibodies. Antibodies for binding to analytes of interest are known in the art or can be easily expressed by methods known in the art.

[0080] The lateral flow device described in the present disclosure includes an immobilized capture material. The immobilized capture material includes an agent capable of binding to an analyte, including free (unlabeled) analyte and / or labeled analyte (such as an analyte bound to an analyte-specific conjugate, as described herein). The immobilized capture material includes (i) an analyte of interest bound by an analyte-specific conjugate, (ii) a free analyte, or (iii) an unlabeled specific binding partner that is specific to an associated specific binding partner that is itself specific to the analyte, as in an indirect assay. As used herein, an "associated specific binding partner" is a specific binding partner that binds to the specific binding partner of the analyte. For example, the associated specific binding partner can include an antibody specific to another antibody, such as a goat anti-human antibody.

[0081] The lateral flow devices described herein may include a "detection region" or "detection zone", which is a region that includes one or more capture regions or capture zones, and where a detectable signal may be detected. The lateral flow devices described herein may include a "capture zone" or "capture region", which is a region of the lateral flow device where a capture substance is immobilized. The lateral flow devices described herein may include one or more capture zones. In some cases, different capture substances are immobilized in different capture zones (such as a first immobilized capture substance in a first capture zone and a second immobilized capture substance in a second capture zone). The multiple capture zones may be in any orientation relative to each other on the lateral flow substrate, for example, a first capture zone may be distal or proximal to a second (or other) capture zone along the path of fluid flow, or vice versa. Alternatively, the first capture zone and the second (or other) capture zone may be aligned along an axis perpendicular to the path of fluid flow such that the fluid contacts them simultaneously or nearly simultaneously.

[0082] The lateral flow device described in the present disclosure includes an immobilized capture material that is immobilized such that the movement of the immobilized capture material is restricted during normal operation of the lateral flow device. For example, the movement of the immobilized capture material is restricted before and after a fluid sample is applied to the lateral flow device. The immobilization of the immobilized capture material can be achieved by physical means such as shielding, electrostatic interactions, hydrogen bonding, bioaffinity, covalent interactions, or a combination thereof. The lateral flow device described in the present disclosure can measure biological entities, including chemical or biochemical compounds produced by organisms, including prokaryotic cell lines, eukaryotic cell lines, mammalian cell lines, microbial cell lines, insect cell lines, plant cell lines, mixed cell lines, naturally occurring cell lines, or synthetically engineered cell lines. Organisms can include large macromolecules, such as proteins, polysaccharides, lipids, and nucleic acids, as well as small molecules, such as primary metabolites, secondary metabolites, and natural products.

[0083] It will be understood that the description, specific examples and data, while indicating exemplary embodiments, are provided for illustration purposes and are not intended to limit the various embodiments of the present disclosure. Various changes and modifications in the present disclosure will become apparent to those skilled in the art from the description and data contained herein and are therefore considered part of the various embodiments of the present disclosure.

Claims

1. 1. A lateral flow assay device for detecting an analyte of interest in a sample, comprising: a first conjugate comprising a first label, an agent configured to specifically bind to said analyte of interest, and a first binding partner; a second conjugate upstream from the first conjugate along a fluid flow path of a lateral flow assay device, wherein the second conjugate comprises a second label and a second binding partner configured to specifically bind to the first binding partner, the second binding partner being an antibody to the first binding partner; and a detection zone downstream of the first conjugate and the second conjugate along the fluid flow path of the lateral flow assay device, the detection zone comprising an immobilized capture agent that specifically binds to the analyte of interest. A lateral flow assay device comprising:

2. The assay device of claim 1, wherein the first label and the second label are the same.

3. The assay device of claim 1, wherein the first conjugate is present in a sample receiving zone of the lateral flow assay device, or the first conjugate is present in a first conjugate zone downstream of the sample receiving zone.

4. The assay device of claim 1, wherein the second conjugate is present in a buffer receiving zone upstream of the sample receiving zone, or the second conjugate is present in a second conjugate zone downstream of the buffer receiving zone and upstream of the sample receiving zone.

5. The assay device of claim 1, wherein the first conjugate is configured to be solubilized and migrate to the detection zone when a fluid sample is applied to the lateral flow assay device.

6. The assay device of claim 5, wherein the second conjugate is configured to be solubilized and migrate to the detection zone after the first conjugate has migrated to the detection zone, and wherein the second conjugate is configured to be solubilized and migrate to the detection zone when a buffer solution is applied to the second conjugate or to a location on the lateral flow assay upstream of the second conjugate.

7. The assay device of claim 1, wherein the agent configured to specifically bind to a target analyte is an antibody or an antibody binding fragment that specifically binds to the target analyte.

8. The assay device of claim 1, wherein the first binding partner is an antigen or a hapten, and the second binding partner is an antibody or an antibody against the hapten.

9. The assay device of claim 1, wherein the target analyte is a biological or environmental substance of interest.

10. The assay device of claim 1, wherein the target analyte is influenza virus.

11. The assay device of claim 10, wherein the influenza virus is an influenza A virus, an influenza B virus or an influenza C virus.

12. The assay device of claim 1, wherein the immobilized capture substance is an antibody or antibody binding fragment that specifically binds to the target analyte.

13. The assay device of claim 1, wherein the test strip comprises a nitrocellulose membrane.

14. The assay device of claim 1, further comprising a control zone comprising an immobilized capture agent that specifically binds to the first conjugate.

15. The assay device of claim 1, wherein the first and second labels are selected from the group consisting of metal nanoparticles, blue latex beads, metal nanoparticles, colored latex particles, colored latex beads, magnetic particles, carbon nanoparticles, quantum dots, upconverting fluorophores, organic fluorophores, textile dyes, enzymes or liposomes.

16. The assay device of claim 1, wherein the first label and the second label comprise gold nanoparticles.

17. The assay device of claim 1, wherein the first label and the second label are configured to generate an optical signal, a fluorescent signal or a magnetic signal.

18. The assay device of claim 1, further comprising a housing including a sample well positioned above or to the side of the first conjugate, a buffer well positioned above or to the side of the second conjugate zone, and a read window accessible to the detection zone.

19. The assay device of claim 18, wherein the buffer well, the second conjugate zone, the sample well and the first conjugate zone are spatially separated along the fluid flow path of the lateral flow assay device.

20. The method of claim 1, further comprising: applying the first conjugate to a lateral flow test strip at or downstream of a sample receiving zone of the lateral flow test strip; and applying the second conjugate to the test strip at a buffer receiving zone upstream or downstream of the sample receiving zone. A method for manufacturing the lateral flow assay device of claim 1, comprising:

21. The method of claim 20, wherein the first conjugate and the second conjugate are applied to the test strip simultaneously.

22. The method of claim 20, wherein the first conjugate and the second conjugate are applied to the test strip by air jet deposition.

23. A method for detecting an analyte of interest in a sample, comprising: a first conjugate comprising a first label, an agent configured to specifically bind to said analyte of interest, and a first binding partner; a second conjugate upstream from the first conjugate along a fluid flow path of a lateral flow assay device, wherein the second conjugate comprises a second label and a second binding partner configured to specifically bind to the first binding partner, the second binding partner being an antibody to the first binding partner; and a detection zone downstream of the first conjugate and the second conjugate along the fluid flow path of the lateral flow assay device, the detection zone comprising an immobilized capture agent that specifically binds to the analyte of interest. applying a sample to a lateral flow assay device comprising: allowing a complex to bind to the immobilized capture agent at the detection zone, wherein the complex comprises the analyte of interest bound to the first conjugate; releasing the second conjugate after binding the complex and allowing it to flow along the fluid flow path of the lateral flow assay device; Binding the second conjugate to the complex bound at the detection zone. The method includes:

24. The method of claim 23, wherein the first label and the second label are the same.

25. The method of claim 23, further comprising detecting a signal generated by the complex and the second conjugate bound in the detection zone.

26. The method of claim 25, further comprising binding a first conjugate that is not bound to the target analyte to the second conjugate that is bound to the complex in the detection zone.

27. The method of claim 23, wherein the first label and the second label are configured to generate an optical signal, a fluorescent signal or a magnetic signal.

28. The method of claim 23, wherein the second conjugate is released 5 seconds, 10 seconds, 15 seconds, 20 seconds, 25 seconds, 30 seconds, 35 seconds, 40 seconds, 45 seconds, 50 seconds, 55 seconds, 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, or 10 minutes after application of a sample to the lateral flow device.

29. The method of claim 28, further comprising the steps of: binding a complex to the immobilized capture agent at the detection zone; labeling the analyte of interest with the first conjugate to form a complex; and binding said complex to said immobilized capture agent at said detection zone; 24. The method of claim 23, comprising:

30. The method of claim 23, wherein releasing the second conjugate comprises applying a buffer solution to the second conjugate or to a location on the lateral flow assay device upstream of the second conjugate.

31. The method of claim 30, wherein applying the buffer comprises pouring the buffer into a buffer receiving well positioned above or upstream of the second conjugate.

32. A sample receiving zone comprising a first label, an agent configured to specifically bind to the analyte of interest, and a first conjugate comprising a first binding partner; a buffer receiving zone upstream of the sample receiving zone, wherein the buffer receiving zone comprises a second conjugate comprising a second label and a second binding partner configured to specifically bind to the first binding partner; a detection zone downstream of the sample receiving zone, the detection zone including an immobilized capture material that specifically binds to the analyte of interest; An assay test strip comprising:

33. The assay test strip of claim 32, wherein the assay test strip comprises a back card, a conjugate pad, a nitrocellulose membrane, and an absorbent pad.

34. The assay test strip of claim 32. a reader including a light source and a detector; and Data Analyzer A diagnostic test system comprising:

35. The diagnostic testing system of claim 34, wherein the reader is configured to obtain an optical signal at a detection zone on the test strip.

36. The diagnostic testing system of claim 35, wherein the data analyzer is configured to process the optical signal obtained by the reader.